Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu3F8 and GM-CSF in Recurrent Osteosarcoma
NCT02502786Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2015
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in osteosarcoma (OS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Event-Free Survival at 12 months. Started Jul 2015; status: active, not recruiting.
02
Drugs
naxitamab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02502786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502786.